Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (1y) (2011 - 2025)
Anika Therapeutics (ANIK) Net Income towards Common Stockholders Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -304.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.04% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -17.29% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 7.59% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -2,482.61% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 34.33% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 390.91% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 182.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 92.21% |
| Sep 30, 2025 | 103.01% |
| Jun 30, 2025 | -72.40% |
| Mar 31, 2025 | 64.23% |
| Dec 31, 2024 | -219.74% |
| Sep 30, 2024 | -329.32% |
| Jun 30, 2024 | 189.49% |
| Mar 31, 2024 | 75.20% |
| Dec 31, 2023 | 60.71% |
| Sep 30, 2023 | -57.11% |
| Jun 30, 2023 | 3.59% |
| Mar 31, 2023 | -254.68% |
| Dec 31, 2022 | 411.38% |
| Sep 30, 2022 | -853.99% |
| Jun 30, 2022 | -143.54% |
| Mar 31, 2022 | -202.47% |
| Dec 31, 2021 | 79.39% |
| Sep 30, 2021 | 108.61% |
| Jun 30, 2021 | 184.75% |
| Mar 31, 2021 | -50.84% |